Progression of HIV-Disease Under Low Dose Corticosteroids
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
There has been reports that low dose prednisolone stabilizes CD4-counts in HIV infected
individuals. However, until now, there are no prospective randomized studies on the use of
corticosteroids in latent HIV disease. Furthermore, low dose prednisolone (5 mg/d) is not
sufficient tested for the risks and benefit for HIV patients especially for those living in
poor settings with a higher risk of infections. This study will assess the benefit and the
safety profile for low dose prednisolone therapy for patients in a region with limited
resources and high prevalence of infections.
Phase:
Phase 2
Details
Lead Sponsor:
Medical Mission Institute, Germany
Collaborators:
Action Medeor Evangelisches Studienwerk Villigst, Germany Georg Friedrich Rexroth Stiftung, Lohr, Germany German Leprosy and Tuberculosis Relief Association University of Wuerzburg